000			nab a22 7a 4500
999			_c16649 _d16649
003			PC16649
005			20230610062758.0
008			211108b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91082 _aCiruelos Gil, Eva María _eOncología Médica
100			_92957 _aPascual Martínez, Pascual _eOncología Médica
100			_92958 _aArroyo Vozmediano, María Luisa _eObstetricia y Ginecología
100			_92959 _aBlanco Guerrero, Marta _eObstetricia y Ginecología
100			_9432 _aManso Sánchez, Luis _eOncología Médica
100			_92960 _aParrilla Rubio, Lucía _eOncología Médica
100			_92961 _aMuñoz, César _eOncología Médica
100			_9301 _aVega Alonso, Estela _eOncología Médica
100			_92962 _aCalderón, Monica Jackelin _eOncología Médica
100			_92963 _aSancho, Blanca _eObstetricia y Ginecología
100			_91181 _aCortés-Funes Castro, Hernán _eOncología Médica
245	0	4	_aThe therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. _h[revisión]
260			_bThe Breast : official journal of the European Society of Mastology, _c2014
300			_a23(3):201-8.
500			_aFormato Vancouver: Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014 Jun;23(3):201-8.
501			_aPMID: 24589524
504			_aContiene 51 referencias
520			_aAlthough selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant. Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy. The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs. Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile. In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.
710			_9303 _aServicio de Oncología Médica
710			_9427 _aServicio de Obstetricia y Ginecología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16649.pdf _ySolicitar documento
942			_2ddc _cREV _n0